Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2016 Nov;101(11):4322-4328. Epub 2016 Oct 18.

Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial.

Author information

1
Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics and Gynecological Oncology (B.B., J.W.-B., R.Z.S., L.P.), Poznan University of Medical Sciences, 60-535 Poznan, Poland; and Division of Reproductive Endocrinology and Infertility, Department of Reproductive Medicine (A.J.D.), University of California-San Diego, LA Jolla, California, 92093-0633.

Abstract

CONTEXT:

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Hyperandrogenism is the central feature of PCOS. Studies on isolated ovarian theca-interstitial cells suggest that resveratrol, a natural polyphenol, reduces androgen production.

OBJECTIVE:

This study was designed to evaluate endocrine and metabolic effects of resveratrol on PCOS.

DESIGN AND SETTING:

This was a randomized (1:1) double-blind, placebo-controlled trial that evaluated the effects of resveratrol over a period of 3 months in an academic hospital.

PATIENTS AND OTHER PARTICIPANTS:

Subjects with PCOS were identified according to the Rotterdam criteria. Thirty-four subjects were enrolled and 30 subjects completed the trial. Evaluations were performed at baseline and repeated after 3 months of treatment.

INTERVENTION:

Resveratrol (1,500 mg p.o.) or placebo were administered daily.

MAIN OUTCOME MEASURE:

Primary outcome was the change in the serum total T.

RESULTS:

Resveratrol treatment led to a significant decrease of total T by 23.1% (P = .01). In parallel, resveratrol induced a 22.2% decrease of dehydroepiandrosterone sulfate (P = .01), a decrease of fasting insulin level by 31.8% (P = .007) and an increase of the Insulin Sensitivity Index (Matsuda and DeFronzo) by 66.3% (P = .04). Levels of gonadotropins, the lipid profile as well as markers of inflammation and endothelial function were not significantly altered.

CONCLUSIONS:

Resveratrol significantly reduced ovarian and adrenal androgens. This effect may be, at least in part, related to an improvement of insulin sensitivity and a decline of insulin level.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01720459.

PMID:
27754722
DOI:
10.1210/jc.2016-1858
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center